Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Xilio Therapeutics Q1 EPS $(0.18) Misses $0.10 Estimate, Sales $2.93M Miss $4.40M Estimate

Author: Benzinga Newsdesk | May 08, 2025 07:38am
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.10 by 280 percent. This is a 69.49 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $2.93 million which missed the analyst consensus estimate of $4.40 million by 33.41 percent.

Posted In: XLO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist